Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnson Matthey, Victrex, Evolution

Tue, 19th Jul 2011 12:07

Prime Markets has suggested buying chemicals group Johnson Matthey, saying that Tuesday's trading statement represents an attractive entry point in the short and long term for investors.The company, focused in catalysis, precious metals, fine chemicals and process technology, said that it continued to make good progress in the first quarter, with adjusted pre-tax profits up by 19% to £98.2m, "principally due to higher demand for products and operational leverage," noted head of dealing Richard Curr."Now at an attractive entry point as the shares bounce off the all important 200-day moving average line, there is a short term momentum trade opportunity off the back of today's statement to upper resistance levels up to 2,100p over the next few days."Prime Markets gives the group a 2,123p target price.After raising its earnings forecasts for plastics group Victrex, UBS upgraded plastics the firm to neutral, from sell, saying that it has strong growth and profitability prospects.The broker notes that metal replacement is becoming increasingly important as companies seek alternatives which are recyclable, reduce weight and fuel consumption: "Victrex PEEK polymers satisfy these criteria."UBS raised its target price from 1,320p to 1,500p.Peel Hunt reiterated its buy recommendation on investment house Evolution Group as the company announced the potential acquisition of BNP Paribas Private Investment Management."The earnings mix of the group is shifting towards being led by the Wealth management division (we forecasts 52% of revenue from that source for 2011 up from 47% as at 2010). This acquisition only adds to this proportion and as this continues the group should begin to trade on a higher multiple," said analyst Henry Biddle.A target price of 86p was kept.BC
More News
22 Mar 2021 14:32

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

IN BRIEF: Evgen Pharma names Helen Kuhlman as chief business officer

Read more
22 Mar 2021 09:08

Evgen appoints Helen Kuhlman as chief business officer

(Sharecast News) - Clinical-stage drug development company Evgen announced on Monday that Helen Kuhlman had been appointed to the post of chief business officer, taking up the role from 1 April.

Read more
11 Mar 2021 20:08

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

IN BRIEF: Evgen says no patient safety concerns in STAR Covid-19 trial

Read more
11 Mar 2021 15:12

Evgen Covid-19 trial given all-clear on safety and data

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Thursday that after a review of the first 60 patients enrolled, the data safety monitoring committee for the 'STAR' Covid-19 trial had concluded that there were no concerns over patient safety or data quality that would prevent its continuation.

Read more
3 Mar 2021 20:16

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

TRADING UPDATES: Cambria drives on amid virus; Argo crypto mining up

Read more
24 Feb 2021 16:09

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Feb 2021 15:10

Evgen makes progress with recruitment in 'STAR' trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma said on Wednesday that a total of 102 patients had been recruited and randomised to the 'STAR', or 'SFX-01 Treatment for Acute Respiratory infections', trial.

Read more
17 Feb 2021 11:15

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

IN BRIEF: Evgen Pharma Recruits Over 100 For Respiratory Drug Trial

Read more
3 Feb 2021 11:49

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

IN BRIEF: Intuitive Investments Buys Shares in Evgen For GBP175,000

Read more
2 Feb 2021 17:45

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

IN BRIEF: Evgen Pharma's GBP11 Fundraise To Support Lead Candidate

Read more
22 Jan 2021 08:53

Evgen Shares Rise On Further Positive Test Results For SFX-01

Evgen Shares Rise On Further Positive Test Results For SFX-01

Read more
21 Jan 2021 13:20

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

IN BRIEF: Evgen Pharma Notes Positive Preclinical Data For SFX-01

Read more
19 Jan 2021 17:34

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

IN BRIEF: Evgen Pharma Recruits Patients For STAR-Covid-19 Trial

Read more
10 Dec 2020 17:07

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

UK EARNINGS SUMMARY: Character Group Lowers Dividend As Profit Drops

Read more
10 Dec 2020 15:45

Evgen Pharma performs in line with forecasts in first half

(Sharecast News) - Clinical-stage drug development company Evgen Pharma reported financial performance in line with its expectations in its first half on Thursday, with revenue coming in at £0.19m, compared to nil a year earlier.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.